TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Other Events

ME Staff 8-k
-
0
TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Other Events

TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Other Events
Item 9.01 Other Events.

On October11, 2018, Trevena,Inc. (the “Company”) issued a press release announcing the outcome of the meeting of the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss the Company’s lead investigational product, oliceridine.

A copy of the press release is furnished hereto as Exhibit99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number

Description

99.1

Press Release dated October11, 2018


TREVENA INC Exhibit
EX-99.1 2 a18-36145_2ex99d1.htm EX-99.1 Exhibit 99.1   Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome   CHESTERBROOK,…
To view the full exhibit click here

About TREVENA,INC. (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.